This is the published version of a paper published in *British Journal of Anaesthesia*.

Citation for the original published paper (version of record):

*British Journal of Anaesthesia*, 121(1): 281-290
https://doi.org/10.1016/j.bja.2018.04.008

Access to the published version may require subscription.

N.B. When citing this work, cite the original published paper.

Permanent link to this version:
http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-150371
Comparative effects of dexmedetomidine, propofol, sevoflurane, and S-ketamine on regional cerebral glucose metabolism in humans: a positron emission tomography study

L. Laaksonen1,2,*, M. Kallioinen2, J. Långsjo3, T. Laitio2, A. Scheinin1,2, J. Scheinin4, K. Kaisti5, A. Maksimow2, R. E. Kallionpää2,5, V. Rajala2, J. Johansson1,7, O. Kantonen1,2,8, M. Nyman9, S. Siren10, K. Valli2,6,11, A. Revonsuo6,11, O. Solin1, T. Vahlberg12, M. Alkire8 and H. Scheinin1,2,13

1Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland, 2Department of Perioperative Services, Intensive Care and Pain Medicine, Turku University Hospital, Turku, Finland, 3Department of Intensive Care, Tampere University Hospital, Tampere, Finland, 4Department of Anaesthesiology, Kuopio University Hospital, Kuopio, Finland, 5Department of Anaesthesiology and Intensive Care, Oulu University Hospital, Oulu, Finland, 6Department of Psychology and Speech-Language Pathology, Turku Brain and Mind Center, University of Turku, Turku, Finland, 7Department of Radiation Sciences, Umeå University, Umeå, Sweden, 8University of California, Irvine, CA, USA, 9Department of Radiology, Turku University Hospital, Turku, Finland, 10Institute of Biomedicine, University of Turku, Unit of Clinical Pharmacology, Turku University Hospital, Turku, Finland, 11Department of Cognitive Neuroscience and Philosophy, School of Bioscience, University of Skövde, Sweden, 12Department of Clinical Medicine, Biostatistics, University of Turku and Turku University Hospital, Turku, Finland and 13Integrative Physiology and Pharmacology, Institute of Biomedicine, University of Turku, Turku, Finland

*Corresponding author. E-mail: lilaak@utu.fi

Abstract

Introduction: The highly selective α₂-agonist dexmedetomidine has become a popular sedative for neurointensive care patients. However, earlier studies have raised concern that dexmedetomidine might reduce cerebral blood flow without a concomitant decrease in metabolism. Here, we compared the effects of dexmedetomidine on the regional cerebral metabolic rate of glucose (CMRglu) with three commonly used anaesthetic drugs at equi-sedative doses.

Methods: One hundred and sixty healthy male subjects were randomised to EC50 for verbal command of dexmedetomidine (1.5 ng ml⁻¹; n=40), propofol (1.7 μg ml⁻¹; n=40), sevoflurane (0.9% end-tidal; n=40) or S-ketamine (0.75 μg ml⁻¹; n=20) or placebo (n=20). Anaesthetics were administered using target-controlled infusion or vapouriser with end-tidal monitoring. 18F-labelled fluorodeoxyglucose was administered 20 min after commencement of anaesthetic.
Different anaesthetics produce characteristic effects on cerebral blood flow (CBF) and metabolism. While sevoflurane decreases cerebral metabolism more than CBF, propofol induces a proportional decrease in both measures. For this reason, propofol has been deemed particularly suitable for neurosurgical and neurointensive care patients. S-ketamine has been demonstrated to increase glucose metabolism in certain regions of the brain and to induce a global increase in CBF. Although dexmedetomidine has become a popular sedative for neurointensive care patients, its effects on cerebral glucose metabolism have not been properly characterised in humans.

Dexmedetomidine is an α2-adrenoceptor agonist with unique properties; it induces sufficient sedation while allowing patient arousal and awakening without changing infusion rate. This is a valuable feature, especially in intensive care patients, who need frequent assessment of their neurological state. In addition, dexmedetomidine has mild analgesic properties and minimal respiratory effects. Furthermore, experimental studies have suggested neuromodulatory properties of dexmedetomidine, but this has not been established in humans. In early animal studies, dexmedetomidine was found to reduce CBF with no effect on the cerebral metabolic rate of oxygen. This raised concern that the decreased blood flow might be inadequate for the cerebral metabolic needs. Studies in humans have, however, suggested that dexmedetomidine proportionally decreases CBF and oxygen metabolism. Nevertheless, uncertainty remains on this issue.

We compared the effects of dexmedetomidine, propofol, sevoflurane, S-ketamine, and placebo on the regional cerebral metabolic rate of glucose (CMRglu) with high-resolution positron emission tomography (PET) imaging. Our aim was to establish the relative potencies of these four anaesthetics with different mechanisms of action, all given at equi-sedative doses.

**Methods**

**Trial design and participants**

We conducted an open-label, randomised, controlled, parallel group, phase IV clinical drug trial at the Turku PET Centre, University of Turku, Finland. The study (ClinicalTrials.gov Identifier NCT02624401) was approved by the Ethics Committee of the Hospital District of Southwest Finland and the Finnish Medicines Agency Fimea (EudraCT 2015-004982-10).

Inclusion criteria were male sex, age 18–30 yr, normal hearing, right handedness, good sleep quality, ASA physical status class 1, fluency in the Finnish language and normal results in a thorough physical examination and laboratory tests including drug screening. Use of any medication or alcohol was prohibited for 48 h and caffeine products for 10–12 h before the study session. All subjects fasted from the previous midnight. Written informed consent was obtained from all subjects according to the Declaration of Helsinki.

The goal was to have 160 subjects in each group, except 20 in the S-ketamine and placebo groups) subjects with complete data, and because of 20 premature withdrawals or dropouts (see Results), 180 subjects were recruited. Subjects were randomised with balanced permuted block sizes of 16 to receive either dexmedetomidine (Dexdor 100 μg ml⁻¹; Orion Pharma, Espoo, Finland), propofol (Propolipid 10 mg ml⁻¹; Fresenius Kabi, Uppsala, Sweden), sevoflurane (Sevorane 100%; Abbvie, Espoo, Finland), S-ketamine (Ketanest-S 25 mg ml⁻¹; Pfizer, Helsinki, Finland) or saline placebo. The person (H.S.) responsible for randomisation did not recruit the subjects to ensure random allocation of the treatments. Baseline characteristics of the subjects are shown in Table 1.

**Anaesthetic protocol and monitoring**

A radial artery was cannulated for all blood samplings and two forearm venous catheters were placed for administration of anaesthetics and Ringer’s acetate (at a standard rate of ~100 ml h⁻¹), and ¹⁸F-labelled fluorodeoxyglucose (¹⁸F-FDG). Subjects breathed room air.
The study outline and sequence of events are shown in Fig. 1. The drug administration protocol included a 20 min stabilisation phase, followed by a 40 min pseudosteady-state phase. I.V. anaesthetics were administered using target-controlled infusion with a Harvard 22 syringe pump (Harvard Apparatus, South Natick, MA, USA) connected to a portable computer running Stanpump software (www.opentci.org/code/stanpump) with previously reported pharmacokinetic parameters. In each of the drug groups, the aim was to achieve a sample where 50% of subjects were unresponsive and 50% maintained responsiveness, defined as the 50% effective concentration for loss of responsiveness (LOR) to verbal command (i.e. EC$_{50}$ for LOR) or minimum alveolar concentration (MAC) for LOR (i.e. MAC$_{LOR}$) for sevoflurane. The selected EC$_{50}$ for LOR values were based on previous studies: 1.5 ng ml$^{-1}$ for dexmedetomidine, 1.7 µg ml$^{-1}$ for propofol, and 0.75 µg ml$^{-1}$ for S-ketamine. Sevoflurane was administered at an end-tidal MAC$_{LOR}$ target of 0.9%. Sevoflurane group subjects wore a face mask tightened with a rubber strap with fresh gas flow set at 6 L min$^{-1}$. After 60 min of drug administration, subjects were transferred to the PET scanner room for a 30 min PET scan (see below). Peripheral oxygen saturation, ECG, and end-tidal carbon dioxide were monitored continuously during the study. Blood pressure was measured non-invasively at the beginning and end of drug administration to avoid possible cuff pain and ensuing arousal during PET data acquisition. A Datex-Ohmeda S/5 anaesthesia monitor (Datex-Ohmeda Division, Instrumentarium Corp., General Electric Company, Helsinki, Finland) and a portable computer running the S5 Collect software (Collect version 4.0, GE Healthcare) were used to record and store all vital parameters.

Subjects were classified as responsive or unresponsive by asking them to press a custom-made handle secured on both wrists. A prerecorded request ‘press the handles twice’ was delivered via headphones using the Presentation 17.0 stimulus delivery and experimental control software system (Neurobehavioral Systems Inc, Berkeley, CA, USA). Testing was

<table>
<thead>
<tr>
<th>Number of subjects</th>
<th>Height (cm)</th>
<th>Weight (kg)</th>
<th>Age (yr)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dexmedetomidine</td>
<td>40</td>
<td>179.1</td>
<td>77.3</td>
</tr>
<tr>
<td>Propofol</td>
<td>40</td>
<td>180.5</td>
<td>77.6</td>
</tr>
<tr>
<td>Sevoflurane</td>
<td>40</td>
<td>179.7</td>
<td>79.5</td>
</tr>
<tr>
<td>S-Ketamine</td>
<td>20</td>
<td>182.7</td>
<td>79.9</td>
</tr>
<tr>
<td>Placebo</td>
<td>20</td>
<td>182.4</td>
<td>82.9</td>
</tr>
</tbody>
</table>

Table 1 Height, weight and age of subjects

The study design, sequence of events and timing of measurements and blood samples. EC$_{50}$ for LOR - Effective concentration 50 for loss of responsiveness; MAC$_{LOR}$, minimum alveolar concentration for LOR; $[^{18}F]$FDG, $^{18}$F-labeled fluorodeoxyglucose; CMR$_{glu}$, cerebral metabolic rate of glucose; PET, positron emission tomography.
performed just before injection of $[^{18}F]$FDG. Concentrations of the i.v. anaesthetics in plasma were determined at baseline and at 19, 30, 40 and 50 min after start of the infusion using validated methods. High-performance liquid chromatography (HPLC) with tandem mass spectrometry was used for dexmedetomidine and S-ketamine. Propofol concentrations were measured with HPLC and fluorescence detection. Interassay coefficients of variation in the relevant concentration ranges were 1.2–2.9%, 3.7–8.0% and 0.7–2.2%, respectively.

**PET data acquisition and assessment**

$[^{18}F]$FDG was used as the PET tracer to quantify CMR$_{\text{glu}}$ in 15 brain regions of interest (ROIs). $^{18}$F was produced by irradiating enriched $[^{18}O]H_2O$ with protons (cyclotron CC 18/9, D.V. Efremov Institute, St. Petersburg, Russia). $^{[18}F]$FDG was synthesised according to GMP regulations using an automated synthesis device (Fastlab; GE Healthcare, Chicago, IL, USA). Radiochemical purity of the product exceeded 95%. Anatomical reference MRI were obtained from each participant separately with a Philips Ingenuity PET-MR 3T scanner (Philips Medical Systems, Best, The Netherlands).

The 300 MBq dose of $[^{18}F]$FDG was administered 20 min after commencement of drug administration using a Rad Injector (Tema Sinergie, Faenza, Italy). A Karl100 (Tema Sinergie, Faenza, Italy) device was used for safe dispensing of the radiopharmaceutical into a shielded syringe. After the 40 min pseudo-steady-state phase, retention of $[^{18}F]$FDG was considered to be stabilised, administration of anaesthetic was terminated, and a 30 min PET scan was performed followed by a transmission scan using a High Resolution Research Tomograph, a dual-layer crystal-detector scanner with an isotropic 2.5 mm intrinsic spatial resolution (HRRT; Siemens Medical Systems, Best, The Netherlands).

The 300 MBq dose of $[^{18}F]$FDG was administered 20 min after commencement of drug administration using a Rad Injector (Tema Sinergie, Faenza, Italy). A Karl100 (Tema Sinergie, Faenza, Italy) device was used for safe dispensing of the radiopharmaceutical into a shielded syringe. After the 40 min pseudo-steady-state phase, retention of $[^{18}F]$FDG was considered to be stabilised, administration of anaesthetic was terminated, and a 30 min PET scan was performed followed by a transmission scan using a High Resolution Research Tomograph, a dual-layer crystal-detector scanner with an isotropic 2.5 mm intrinsic spatial resolution (HRRT; Siemens Medical Systems, Best, The Netherlands).

The 300 MBq dose of $[^{18}F]$FDG was administered 20 min after commencement of drug administration using a Rad Injector (Tema Sinergie, Faenza, Italy). A Karl100 (Tema Sinergie, Faenza, Italy) device was used for safe dispensing of the radiopharmaceutical into a shielded syringe. After the 40 min pseudo-steady-state phase, retention of $[^{18}F]$FDG was considered to be stabilised, administration of anaesthetic was terminated, and a 30 min PET scan was performed followed by a transmission scan using a High Resolution Research Tomograph, a dual-layer crystal-detector scanner with an isotropic 2.5 mm intrinsic spatial resolution (HRRT; Siemens Medical Systems, Best, The Netherlands).

All study sessions were conducted in a quiet, dimly lit room. PET emission data acquisition in list-mode format was initiated approximately 45–50 min after tracer injection. The subject’s head was fixed to the headrest of the scanner using an individual thermoplastic mask made before the scanning. Head motion was monitored using a high-precision, stereotactic tracking device (Polaris Vicra; Northern Digital, Waterloo, Ontario, Canada) attached to the subject’s head. Image formation was conducted using an iterative OSEM algorithm with resolution modelling (12 iterations, 16 subsets, including corrections for attenuation, scatter, and random events). PET emission data were histogrammed into a single 30 min frame reflecting the assumption of steady $[^{18}F]$FDG retention at this late time window. If a head movement $>$2.5 mm was detected, scans were divided into subframes and subsequently co-registered into a single 30 min frame by using the multiple acquisition frame image reconstruction procedure and the attenuation correction realignment algorithm. This procedure was used in four dexmedetomidine scans, two S-ketamine scans, and two sevoflurane scans.

Twenty-four arterial tracer activity blood samples were collected for tracer kinetic modelling. Immediately after the injection of $[^{18}F]$FDG, the first 12 samples were obtained at intervals of 15 s, followed by additional samples at 4, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, and 90 min. In addition, samples were drawn to measure plasma glucose concentrations at baseline, and at 30, 60, and 90 min after the injection of $[^{18}F]$FDG.

**Data analysis**

Calculation of voxel-wise maps of CMR$_{\text{glu}}$ was conducted on the basis of average $[^{18}F]$FDG retention at 50–80 min after tracer injection and plasma radioactivity data. Individual MRIs were then co-registered with the parametric images of subjects using statistical parametric mapping software (version 8, SPM8; Wellcome Institute, London, UK).

The voxel-wise maps of CMR$_{\text{glu}}$ were calculated according to the equation:

$$\text{CMR}_{\text{glu}} = \frac{\text{FUR} \times C_{\text{glu}}}{\text{LC}}$$

where FUR is the fractional uptake rate of $[^{18}F]$FDG relative to the integral (0–90 min) of $[^{18}F]$FDG concentration in plasma, $C_{\text{glu}}$ is plasma glucose concentration, and LC is the lumped constant (0.65). Using the average brain tissue density (1.04 g ml$^{-1}$), CMR$_{\text{glu}}$ values were converted into units of µmol 100 g$^{-1}$ min$^{-1}$.

Voxel-average, regional CMR$_{\text{glu}}$ values were extracted within 15 ROIs including the prefrontal cortex, parietal cortex, lateral temporal cortex, lateral occipital cortex, precuneus, anterior cingulate gyrus, posterior cingulate gyrus, entorhinal cortex, striatum, cerebellum, insula, thalamus, amygdala, pallidum, and hippocampus. ROIs were generated automatically with the help of individual T1-weighted MRI data and FreeSurfer software (version 5.3; http://surfer.nmr.mgh.harvard.edu; see Supplementary material).

**Statistical analyses**

The statistical analyses of regional CMR$_{\text{glu}}$ data were performed with analysis of variance (ANOVA). First, all regions were analysed together using repeated measures ANOVA with region as a within factor and treatment as a between factor. If a

<table>
<thead>
<tr>
<th>Number of subjects</th>
<th>Baseline</th>
<th>19 min</th>
<th>30 min</th>
<th>40 min</th>
<th>50 min</th>
<th>Targeted</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
<td>SD</td>
</tr>
<tr>
<td>Dexmedetomidine (ng ml$^{-1}$)</td>
<td>40</td>
<td>0.00</td>
<td>0.00</td>
<td>2.17</td>
<td>0.43</td>
<td>2.13</td>
</tr>
<tr>
<td>Propofol (µg ml$^{-1}$)</td>
<td>40</td>
<td>0.00</td>
<td>0.00</td>
<td>1.82</td>
<td>0.38</td>
<td>1.74</td>
</tr>
<tr>
<td>Sevoflurane (end-tidal%)</td>
<td>40</td>
<td>0.00</td>
<td>0.00</td>
<td>0.90</td>
<td>0.05</td>
<td>0.92</td>
</tr>
<tr>
<td>S-Ketamine (µg ml$^{-1}$)</td>
<td>20</td>
<td>0.00</td>
<td>0.00</td>
<td>0.85</td>
<td>0.18</td>
<td>0.99</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 3 Cerebral metabolic rate of glucose (μmol 100 g⁻¹ min⁻¹) in the dexmedetomidine, propofol, sevoflurane, S-ketamine, and placebo groups. Tukey-corrected P-values for significant paired comparisons (*drug vs placebo) and between drugs (†dexmedetomidine vs propofol, ‡dexmedetomidine vs sevoflurane, §drug vs S-ketamine). The number of symbols refer to level of significance (e.g. *P<0.05, **P<0.01 and ***P<0.001). *Degrees of freedom

<table>
<thead>
<tr>
<th>Brain area</th>
<th>Dexmedetomidine</th>
<th>Propofol</th>
<th>Sevoflurane</th>
<th>S-Ketamine</th>
<th>Placebo</th>
<th>One-way ANOVA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
<td>% of placebo</td>
<td>Mean</td>
<td>SD</td>
<td>% of placebo</td>
</tr>
<tr>
<td>Prefrontal cortex</td>
<td>23.7</td>
<td>2.0</td>
<td>62.4 ***</td>
<td>27.1</td>
<td>3.5</td>
<td>71.2 ***</td>
</tr>
<tr>
<td>Parietal cortex</td>
<td>23.2</td>
<td>2.1</td>
<td>61.6 ***</td>
<td>25.9</td>
<td>3.8</td>
<td>68.7 ***</td>
</tr>
<tr>
<td>Lateral temporal cortex</td>
<td>21.4</td>
<td>2.0</td>
<td>64.9 ***</td>
<td>24.1</td>
<td>3.6</td>
<td>72.8 ***</td>
</tr>
<tr>
<td>Lateral occipital cortex</td>
<td>21.6</td>
<td>1.9</td>
<td>62.9 ***</td>
<td>22.7</td>
<td>3.3</td>
<td>66.2 ***</td>
</tr>
<tr>
<td>Precuneus</td>
<td>24.8</td>
<td>2.3</td>
<td>60.6 ***</td>
<td>27.9</td>
<td>3.8</td>
<td>68.2 ***</td>
</tr>
<tr>
<td>Anterior cingulate gyrus</td>
<td>19.9</td>
<td>1.7</td>
<td>65.2 ***</td>
<td>24.0</td>
<td>3.3</td>
<td>78.6 ***</td>
</tr>
<tr>
<td>Posterior cingulate gyrus</td>
<td>23.3</td>
<td>2.4</td>
<td>60.7 ***</td>
<td>26.7</td>
<td>3.6</td>
<td>69.6 ***</td>
</tr>
<tr>
<td>Entorhinal cortex</td>
<td>14.6</td>
<td>1.6</td>
<td>66.3 ***</td>
<td>17.1</td>
<td>2.5</td>
<td>77.9 ***</td>
</tr>
<tr>
<td>Striatum</td>
<td>22.5</td>
<td>2.2</td>
<td>64.1 ***</td>
<td>17.1</td>
<td>3.7</td>
<td>78.8 ***</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>16.3</td>
<td>1.6</td>
<td>62.6 ***</td>
<td>18.8</td>
<td>2.6</td>
<td>72.3 ***</td>
</tr>
<tr>
<td>Insula</td>
<td>20.4</td>
<td>1.9</td>
<td>65.7 ***</td>
<td>23.5</td>
<td>3.0</td>
<td>75.6 ***</td>
</tr>
<tr>
<td>Thalamus</td>
<td>17.8</td>
<td>1.6</td>
<td>60.4 ***</td>
<td>21.2</td>
<td>3.1</td>
<td>71.9 ***</td>
</tr>
<tr>
<td>Amygdala</td>
<td>14.1</td>
<td>1.3</td>
<td>69.9 ***</td>
<td>16.4</td>
<td>2.2</td>
<td>81.3 ***</td>
</tr>
<tr>
<td>Pallidum</td>
<td>15.6</td>
<td>2.3</td>
<td>64.7 ***</td>
<td>18.6</td>
<td>2.8</td>
<td>72.2 ***</td>
</tr>
<tr>
<td>Hippocampus</td>
<td>15.5</td>
<td>1.3</td>
<td>67.7 ***</td>
<td>17.6</td>
<td>2.3</td>
<td>77.0 ***</td>
</tr>
<tr>
<td>Whole brain</td>
<td>21.2</td>
<td>1.8</td>
<td>62.8 ***</td>
<td>24.1</td>
<td>3.2</td>
<td>71.4 ***</td>
</tr>
</tbody>
</table>
significant region by treatment interaction was found, the analyses were continued for each region separately and for the whole brain CMR\(_{\text{glu}}\) (aggregate of all 15 ROIs) using one-way ANOVA with treatment as a between factor followed by paired comparisons of the different treatments using Tukey’s post hoc tests for multiple correction. For i.v. anaesthetics, Pearson correlation coefficients were calculated to assess the association between the mean measured drug concentration and whole brain CMR\(_{\text{glu}}\), and \(\chi^2\) testing was used to compare responsiveness at the time of \(^{18}\text{F}\)FDG injection between treatments. The normality of variables was checked using the Kolmogorov–Smirnov test. A two-sided \(P<0.05\) was considered statistically significant. Results are given as mean (standard deviation [SD]) if not stated otherwise. Statistical analyses were performed with SAS System for Windows, version 9.4. (SAS Institute Inc., Cary, NC, USA).

**Results**

Of 180 subjects recruited, 15 withdrew from the study after randomisation. Four sessions (three with S-ketamine, one with sevoflurane) had to be terminated because of excessive motor anxiety. In addition, one subject received only approximately 7% of the planned S-ketamine dose because of a programming error and was therefore excluded. Otherwise, the study was completed as planned. No clinically significant changes were observed in vital parameters (data not shown).

One hundred and sixty subjects were evaluable (40 dexmedetomidine, 40 propofol, 40 sevoflurane, 20 S-ketamine, and 20 placebo) for regional CMR\(_{\text{glu}}\). Measured dexmedetomidine and S-ketamine concentrations were somewhat higher than targeted (Table 2). At the time of \(^{18}\text{F}\)FDG injection, 22 (55%) dexmedetomidine, 18 (45%) propofol, 34 (85%) sevoflurane, nine (45%) S-ketamine, and 0 (0%) placebo subjects were unresponsive to verbal command \([\chi^2(4)=40.43, P<0.001]\). In paired comparisons, all drugs differed from placebo and sevoflurane differed from the other drugs.

Because a significant region by treatment interaction \(P<0.001\) was found in the repeated measures ANOVA, regions were analysed separately. There were statistically significant differences in regional CMR\(_{\text{glu}}\) between groups in all 15 ROIs and their aggregate (whole brain CMR\(_{\text{glu}}\); \(P<0.001\) for all; Table 3, Figs. 2 and 3). In paired comparisons, the dexmedetomidine, propofol and sevoflurane groups differed from the placebo and S-ketamine groups. Dexmedetomidine was associated with the lowest CMR\(_{\text{glu}}\) in all brain regions and differed from all other drugs \(P<0.05\), with the exception that no significant difference was found in the lateral occipital cortex compared with propofol or sevoflurane, and in the cerebellum compared with sevoflurane (Table 3). Compared with placebo, regional CMR\(_{\text{glu}}\) values were 30.1–39.6% lower in the dexmedetomidine group. Propofol and sevoflurane did not differ from each other in any ROI. With S-ketamine, CMR\(_{\text{glu}}\) did not differ from placebo in any of the ROIs studied. There were weak but statistically significant associations between measured drug concentrations and CMR\(_{\text{glu}}\) in the dexmedetomidine and propofol groups (Fig. 4).

**Discussion**

The effects of EC\(_{50}\) doses for LOR of dexmedetomidine, propofol, sevoflurane, and S-ketamine on absolute CMR\(_{\text{glu}}\) were evaluated using state-of-the-art PET methodology. Compared with placebo, significantly lower CMR\(_{\text{glu}}\) values were measured with dexmedetomidine, propofol, and sevoflurane throughout the brain. The greatest suppressive effect was seen with dexmedetomidine, which induced the lowest CMR\(_{\text{glu}}\) in

---

**Fig 2.** Boxplots of regional cerebral metabolic rate of glucose (CMR\(_{\text{glu}}\)) in the 15 analysed regions of interest (ROIs) during dexmedetomidine, propofol, sevoflurane, S-ketamine, and placebo administration in 160 healthy subjects \((P<0.001\) between the treatments in all ROIs). Lowest CMR\(_{\text{glu}}\) values were observed in the dexmedetomidine group (for paired comparisons, see Table 3). Boxes represent lower quartiles, medians and upper quartiles, whiskers represent 1.5×inter-quartile ranges below and above the lower and upper quartiles, respectively. Outlying values are marked with symbols.
nearly all brain regions compared with the other groups. With S-ketamine, CMR$_{\text{Glu}}$ values were comparable with placebo.

Previous studies in laboratory animals and humans have quite consistently demonstrated that dexmedetomidine decreases CBF. $^{17,19,32,33}$ The most convincing evidence was seen in an early human PET study where a $0.628 \text{ ng ml}^{-1}$ average plasma concentration of dexmedetomidine resulted in a 33% global decrease in CBF from baseline. $^{32}$ A reduction in CBF has also been demonstrated with the sagittal sinus outflow technique in two early studies in dogs where dexmedetomidine was given during isoflurane$^{18}$ or halothane$^{17}$ anaesthesia. The most remarkable finding in these studies was that the decrease in CBF was not associated with a concomitant decrease in cerebral oxygen metabolism, which raised concern that dexmedetomidine might cause ischaemia in the brain. $^{17,18}$ In healthy brain with functional flow–metabolism coupling, a reduction in neuronal activity should be accompanied by a parallel decrease in cerebral metabolism and, consequently, CBF. $^{34}$ Dexmedetomidine is known to cause direct vasoconstriction of the cerebral vessels through

**Fig 3.** Boxplots of whole brain cerebral metabolic rate of glucose (CMR$_{\text{Glu}}$) in 160 healthy subjects. CMR$_{\text{Glu}}$ was 63%, 71%, 71%, and 96% of placebo, in the dexmedetomidine, propofol, sevoflurane, and S-ketamine groups, respectively (P<0.001 between the groups). Dexmedetomidine differed from all other groups (for paired comparisons, see Table 3). Boxes represent lower quartiles, medians and upper quartiles, whiskers represent 1.5×inter-quartile ranges below and above the lower and upper quartiles, respectively. Outlying values are marked with symbols.

**Fig 4.** Correlation plots of the associations between the mean measured drug concentration of dexmedetomidine, propofol, and S-ketamine and whole brain cerebral metabolic rate of glucose (CMR$_{\text{Glu}}$). $r=$Pearson correlation coefficient; dashed lines depict the 95% confidence intervals for the regression lines.
activation of postsynaptic α2-adrenoreceptors on vascular smooth muscle cells,35 which, in the absence of a concomitant reduction in cerebral metabolism, might predispose the brain to ischaemia. For this reason, a better understanding regarding the effects of dexmedetomidine on brain metabolism is needed. This would have implications for treatment of patients with compromised brain function who are at high risk for cerebral ischaemia.

Two small clinical trials have addressed the relationship between brain oxygen utilisation and CBF during dexmedetomidine exposure. By using the middle cerebral artery flow velocity technique and oxygen metabolism equivalent estimation based on jugular vein blood samples, it was demonstrated in six healthy human subjects that dexmedetomidine might decrease cerebral oxygen metabolism equivalently to CBF.36 Another study showed that dexmedetomidine did not affect brain tissue oxygen concentration in five neurosurgical patients.37 While these studies were limited by their small sample size, the first study could only offer global relative values and the second study contained many confounding elements including concomitant surgery. Although the latter study could not measure metabolism per se, the preliminary results suggested that dexmedetomidine would not have a direct vasoconstrictive effect that might lead to diminished oxygen delivery to brain tissue.

The most sophisticated previous study on the subject was conducted using combined imaging of CBF with the arterial spin labelling functional MRI technique and [18F]FDG-PET.37 Dexmedetomidine-induced suppression of CBF and CMRglu was observed in the thalamus, the default mode network structures and the frontoparietal regions bilaterally. However, because PET imaging was performed without blood activity sampling, this study could not determine the absolute regional CMRglu effects of dexmedetomidine. The present study resolves this shortcoming and was able to show a significant reduction in absolute regional CMRglu. Given that parallel reductions in CBF have been reported previously,17–19,32,37 the present results alleviate concern for potential harmful effects of dexmedetomidine on coupling between brain metabolism and perfusion.

Numerous studies have shown that propofol and volatile anaesthetics decrease CMRglu, cerebral oxygen metabolism, and CBF.1–11,38,39 Our results are in line with these previous findings. Ketamine or S-ketamine increase CBF, while their metabolic effects are limited to only a slight increase in certain brain regions.12–14 Thus, the present results with S-ketamine, with effects on CMRglu comparable with placebo, are also in agreement with previous findings. However, it is noteworthy that the greatest individual variability in CMRglu was observed in the S-ketamine group (Fig. 2). Here, we provide a definitive answer to anaesthetic potency for reducing CMRglu. Potency for CMRglu reduction in humans follows the rank order of dexmedetomidine→propofol→ketamine→placebo. Sevoflurane decreased metabolism equally to propofol, but the dose was not quite equipotent.

The main limitation of this study was that CBF was not measured together with CMRglu. Thus, we still lack knowledge of the exact metabolism→perfusion effects of dexmedetomidine. However, the clear reduction in CMRglu observed shows that a parsimonious mode of brain activity can be achieved with dexmedetomidine. Second, only healthy male subjects were investigated. The most concerning issue is the direct vasoconstrictive effect of dexmedetomidine, which might increase the risk of cerebral ischaemia, for example in patients with aneurysmal subarachnoid haemorrhage already vulnerable to vasospasm. Still, reduction in brain activity and CMRglu would probably offer some protection against such an effect.

Third, measurements were made for only one target concentration of each of the four anaesthetics. Fourth, our goal of comparing equipotent doses (EC50 for LOR or MACLOR) of anaesthetics was not quite met as 85% of the sevoflurane subjects were unresponsive at the time of [18F]FDG injection, compared with 45–55% in the other drug groups. Despite this shortcoming, CMRglu in the dexmedetomidine group was significantly lower than in the sevoflurane group in the whole brain and in 13 of the 15 ROIs studied.

In conclusion, dexmedetomidine, propofol, and sevoflurane decreased CMRglu in a global manner compared with placebo and S-ketamine, with dexmedetomidine inducing the greatest suppression. The present results alleviate the concern for potential harmful effects of dexmedetomidine on the ratio of cerebral blood flow and metabolism.

Authors’ contributions

Subject recruitment, data collection, and writing the manuscript: L.L.
Data analysis and writing the manuscript: M.K., M.A.
Data collection and writing the manuscript: J.L., T.L., A.S., J.S.
Data collection and review of the manuscript: A.M., K.K., O.K., R.K., V.R., K.V.
Laboratory analysis and review of the manuscript: S.S.
Data analysis and review of the manuscript: J.J., M.N., T.V.
Study design and review of the manuscript: A.R., O.S.
Principal investigator, study design, data analysis, writing the manuscript: H.S.
Review and approval of the final draft of manuscript: all authors.

Acknowledgements

The authors thank the radiographers and anaesthesia nurses at Turku University Hospital for excellent technical assistance.

Appendix A. Supplementary data

Supplementary data related to this article can be found at https://doi.org/10.1016/j.bja.2018.04.008.

Declaration of interest

Dr. Jaakko Långsjo has received a lecture compensation from Orion Pharma and attended an educational congress as a guest of Pfizer. Dr. Långsjo also reports to be a minor shareholder of Orion. Dr. Timo Laitio is a paid consultant of NeuroproteXeon. The rest of the authors declare that they have no conflicts of interest.

Funding

This work was supported by Academy of Finland, Helsinki, Finland (grant numbers 266467, 266434); Jane and Aatos Erkko Foundation, Helsinki, Finland; VSSH-EVO (grant numbers 13323, L3824), Turku, Finland; Doctoral Programme of Clinical Investigation, University of Turku Graduate School, Turku, Finland (A.S.); The Finnish Medical Foundation, Helsinki, Finland (J.L.); The Emil Aaltonen Foundation, Tampere, Finland (J.L.); and The Paulo Foundation, Espoo, Finland (A.M.).
References


5. Alkire MT. Quantitative EEG correlations with brain glucose metabolic rate during anesthesia in volunteers. Anesthesiology 1998; 89: 323–33


19. Alkire MT. Quantitative EEG correlations with brain glucose metabolic rate during anesthesia in volunteers. Anesthesiology 1998; 89: 323–33


33. Alkire MT. Quantitative EEG correlations with brain glucose metabolic rate during anesthesia in volunteers. Anesthesiology 1998; 89: 323–33


34. Roy CS, Sherrington CS. On the regulation of the blood-supply of the brain. J Physiol (Lond) 1890; 11. 85–158.17

Handling editor: H.C. Hemmings Jr